Welcome to our dedicated page for Biomx SEC filings (Ticker: PHGE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
BiomX Inc. (PHGE) SEC filings document a public company whose reported focus has shifted from legacy phage therapy development toward defense, security, and critical infrastructure technology. Recent filings include quarterly reports, amended annual report material, current reports on Form 8-K, shareholder voting disclosures, material agreements, capital-structure items, governance matters, and risk-factor disclosures.
PHGE’s 10-Q filings are important because BiomX reports as a single operating segment and presents its financial information on a consolidated basis. The quarterly filing also states that the company has incurred significant losses and negative cash flows from operations and that these factors raise substantial doubt about its ability to continue as a going concern.
BiomX 8-K filings are especially relevant because recent material-event reports describe the Zorronet acquisition, shareholder approvals, and a framework supply agreement involving Israel Railways. These filings provide details on Zorronet’s AI-powered computer vision, autonomous surveillance, threat detection, object recognition, perimeter intrusion identification, and command-and-control integrations.
Annual reports on 10-K and amended annual reports on 10-K/A provide governance, compensation, equity plan, and business-history context. Proxy materials show shareholder voting matters. Form 4 insider transaction filings, when filed, identify changes in beneficial ownership by company insiders. For PHGE, the most relevant filing themes are Zorronet and DFSL operating disclosures, legacy phage therapy background, going-concern language, governance changes, and material agreements tied to defense and infrastructure markets.
OrbiMed Israel GP Ltd., OrbiMed Israel BioFund GP L.P., Carl L. Gordon and Erez Chimovits filed Amendment No. 6 to their Schedule 13D on BiomX Inc. (ticker PHGE). The amendment is an exit filing that discloses the group has fallen below the 5% ownership threshold.
Key details:
- On 18 June 2025, OrbiMed Israel Partners ("OIP") sold 1,787,767 common shares of BiomX at $0.34 per share.
- After the sale, the group’s beneficial holdings consist solely of 276,150 shares (all issuable upon conversion of 223 Series X Non-Voting Convertible Preferred Stock and 2,538,500 warrants).
- This position represents 1.0% of BiomX’s 26.45 million shares outstanding (including the shares underlying the preferred stock and warrants).
- The filing emphasises that, as of 18 June 2025, the reporting persons are no longer beneficial owners of more than 5% of BiomX’s outstanding shares.
- The investment committee comprising Gordon and Chimovits continues to review the position and may buy or sell additional shares based on market conditions, but no specific future plans were disclosed.
Implications: The disposal of nearly 1.8 million shares by a long-standing institutional holder removes a significant block from the shareholder register and may affect market perception of insider confidence. However, the remaining warrants and preferred shares ensure the group still retains some exposure to BiomX’s future performance.